Temporal Patterns and Drug Resistance in CSF Viral Escape Among ART-Experienced HIV-1 Infected Adults.
Cerebrospinal fluid (CSF) viral escape is an increasingly recognized clinical event among HIV-1-infected adults. We analyzed longitudinal data and drug-resistance mutations to characterize profiles of HIV-1-infected patients on antiretroviral therapy with discordant CSF and plasma HIV-1 RNA levels.



Forty-one cases of CSF escape defined as detectable CSF HIV-1 RNA when plasma levels were undetectable, or HIV-1 RNA >0.5-log higher in CSF than plasma were identified from Boston Hospitals and National NeuroAIDS Tissue Consortium (NNTC) from 2005 to 2016.



Estimated prevalence of CSF escape in Boston and NNTC cohorts was 6.0% and 6.8%, respectively; median age was 50, duration of HIV-1 infection 17 years, CD4 count 329 cells/mm and CD4 nadir 21 cells/mm. Neurological symptoms were present in 30 cases; 4 had repeat episodes of CSF escape. Cases were classified into subtypes based plasma HIV-1 RNA levels in the preceding 24 months: high-level viremia (1000 copies/mL), low-level viremia (LLV: 51-999 copies/mL), and plasma suppression with CSF blip or escape (CSF RNA <200 or ≥200 copies/mL). High-level viremia cases reported more substance abuse, whereas LLV or plasma suppression cases were more neurosymptomatic (81% vs. 53%); 75% of repeat CSF escape cases were classified LLV. M184V/I mutations were identified in 74% of CSF samples when plasma levels were ≤50 copies per milliliter.



Characteristics frequently observed in CSF escape include HIV-1 infection >15 years, previous LLV, and M184V/I mutations in CSF. Classification based on preceding plasma HIV RNA levels provides a useful conceptual framework to identify causal factors and test therapeutics.
*Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA; †Department of Neurology, Massachusetts General Hospital, Boston, MA; ‡Departments of Neurology and Neurosurgery, Boston Medical Center, Boston, MA; §Department of Neurology, Brigham and Womens Hospital, Boston, MA; ‖Division of NeuroImmunology, Beth Israel Deaconess Medical Center, Boston, MA; ¶Department of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA; #Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY; and **Department of Neurological Sciences, Rush University Medical Center, Chicago, IL.
Shibani S
SS
Mukerji
Vikas
V
Misra
David
D
Lorenz
Anna M
AM
Cervantes-Arslanian
Jennifer
J
Lyons
Spyridon
S
Chalkias
Alysse
A
Wurcel
Deirdre
D
Burke
Nagagopal
N
Venna
Susan
S
Morgello
Igor J
IJ
Koralnik
Dana
D
Gabuzda
D018791:CD4 Lymphocyte Count; D024882:Drug Resistance, Viral / Q000187:drug effects*; D005260:Female; D015658:HIV Infections / Q000134:cerebrospinal fluid* / Q000188:drug therapy / Q000276:immunology* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D057131:Immune Evasion / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000235:genetics; D012189:Retrospective Studies; D014481:United States; D019562:Viral Load / Q000187:drug effects
D012367:RNA, Viral